Antabio

436 Rue Pierre et Marie Curie
Labège
31670
France

Show jobs for this employer

About Antabio

Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. Two of Antabio’s programs have received Wellcome Trust Seeding Drug Discovery Awards to date: (i) a novel, safe and efficacious inhibitor of bacterial metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections and (ii) a first-in-class inhibitor of Pseudomonas virulence to be co-administered with standard-of-care antibiotics for the long-term management of chronic respiratory infections. The company’s lead product is expected to enter the clinic in 2019 with a fast track to anticipated marketing approval by 2021. Antabio has built a best in class, international team of experts in the field and is currently seeking to raise additional funds to progress its pipeline up to the next value inflection point. The Company is also looking to in-license additional assets focused on Gram-negative antibiotic resistant therapies.
YEAR FOUNDED:
2009
LEADERSHIP:
Founder and CEO: Marc Lemonnier
CSO: Martin Everett
JOBS:
Please click here for Antabio job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
FOLLOW ANTABIO:

4 articles with Antabio